Mark A. Wilson
2021
In 2021, Mark A. Wilson earned a total compensation of $3.5M as Senior Vice President and General Counsel at Nektar Therapeutics, a 1% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $287,500 |
|---|---|
| Option Awards | $998,320 |
| Salary | $500,000 |
| Stock Awards | $1,707,078 |
| Other | $10,763 |
| Total | $3,503,661 |
Wilson received $1.7M in stock awards, accounting for 49% of the total pay in 2021.
Wilson also received $287.5K in non-equity incentive plan, $998.3K in option awards, $500K in salary and $10.8K in other compensation.
Rankings
In 2021, Mark A. Wilson's compensation ranked 3,823rd out of 12,405 executives tracked by ExecPay. In other words, Wilson earned more than 69.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,823 out of 12,405 | 69th |
Division Manufacturing | 1,565 out of 5,494 | 72nd |
Major group Chemicals And Allied Products | 637 out of 2,369 | 73rd |
Industry group Drugs | 566 out of 2,090 | 73rd |
Industry Pharmaceutical Preparations | 395 out of 1,537 | 74th |
Source: SEC filing on April 29, 2022.
Wilson's colleagues
We found four more compensation records of executives who worked with Mark A. Wilson at Nektar Therapeutics in 2021.
2021
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2021
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2021
Jonathan Zalevsky
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2021
John Northcott
Nektar Therapeutics